Pfizer Inc. (0Q1N.IL)
- Previous Close
22.62 - Open
22.68 - Bid 21.45 x --
- Ask 24.05 x --
- Day's Range
22.68 - 23.00 - 52 Week Range
20.77 - 27.54 - Volume
3,230 - Avg. Volume
282,982 - Market Cap (intraday)
139.397B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
6.12 - EPS (TTM)
3.76 - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield 1.64 (5.31%)
- Ex-Dividend Date Nov 8, 2023
- 1y Target Est
--
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
www.pfizer.com83,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 0Q1N.IL
View MorePerformance Overview: 0Q1N.IL
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0Q1N.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0Q1N.IL
View MoreValuation Measures
Market Cap
129.80B
Enterprise Value
173.77B
Trailing P/E
16.39
Forward P/E
7.75
PEG Ratio (5yr expected)
0.57
Price/Sales (ttm)
2.07
Price/Book (mrq)
1.42
Enterprise Value/Revenue
2.78
Enterprise Value/EBITDA
10.08
Financial Highlights
Profitability and Income Statement
Profit Margin
27.55%
Return on Assets (ttm)
7.63%
Return on Equity (ttm)
23.07%
Revenue (ttm)
77.94B
Net Income Avi to Common (ttm)
21.49B
Diluted EPS (ttm)
3.76
Balance Sheet and Cash Flow
Total Cash (mrq)
44.79B
Total Debt/Equity (mrq)
66.14%
Levered Free Cash Flow (ttm)
12.35B